Atezolizumab is a monoclonal antibody that binds to PD-L1 on cancer cells to enhance T-cell function, and Bevacizumab is a monoclonal antibody that binds circulating VEGF to inhibit angiogenesis. The gene discussed is CD274; the disease is cancer.